🫀 TAVR or SAVR? The 7-Year Truth

New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.

🔎 Highlights

• Composite events: 34.6% (TAVR) vs 37.2% (SAVR)

• Mortality: 19.5% vs 16.8%

• Valve failure: 6.9% vs 7.3%

• Aortic gradients remain low in both groups

💡 Clinical rhythm: less AF with TAVR; more pacemakers and paravalvular leak.

This study reinforces a simple truth: in the right low-risk patient, TAVR is not just less invasive — it's durable.

#Cardiology #StructuralHeart #AorticStenosis #TAVR #SAVR #NEJM